仙琚制药(002332) - 2014 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2014 was CNY 1,190,483,041.23, representing a 4.88% increase compared to CNY 1,135,132,281.64 in the same period last year[21]. - The net profit attributable to shareholders of the listed company decreased by 44.70% to CNY 28,498,147.62 from CNY 51,530,688.53 year-on-year[21]. - Basic and diluted earnings per share both dropped by 40.00% to CNY 0.06 from CNY 0.10 in the same period last year[21]. - The net profit after deducting non-recurring gains and losses was CNY 28,130,424.28, down 45.03% from CNY 51,170,858.71 in the same period last year[21]. - The operating profit decreased by 56.03% to CNY 2,680.96 million, reflecting increased costs and expenses[32]. - The company expects a net profit attributable to shareholders for the period from January to September 2014 to range between 34.07 million and 45.43 million yuan, representing a decrease of 20.00% to 40.00% compared to the same period in 2013[66]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -77,011,994.03, slightly worse than CNY -75,363,104.90 in the previous year, a decline of 2.19%[21]. - The company's cash flow from operating activities was negative at CNY -77,011,994.03, indicating cash management challenges[33]. - Total cash inflow from operating activities was 1,315,823,565.50 CNY, while cash outflow was 1,392,835,559.53 CNY, resulting in a net cash outflow of 77,011,994.03 CNY[132]. - The total cash and cash equivalents at the end of the period were 217,510,741.40 CNY, down from 220,695,247.25 CNY in the previous period[133]. - The company reported a net increase in cash and cash equivalents of -60,812,277.75 CNY, compared to -66,937,137.56 CNY in the previous period, showing a slight improvement in cash management[133]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,804,479,514.07, an increase of 1.84% from CNY 2,753,781,655.82 at the end of the previous year[21]. - The total liabilities increased slightly to CNY 1,597,971,746.75 from CNY 1,571,760,413.78, indicating a growth of about 1.7%[120]. - Current assets totaled CNY 1,453,376,579.63, up from CNY 1,400,830,314.91 at the start of the period, reflecting a growth of approximately 3.7%[118]. - Accounts receivable increased significantly to CNY 450,788,663.82 from CNY 310,541,641.75, representing a growth of approximately 45%[118]. - Inventory decreased to CNY 436,329,471.14 from CNY 508,772,201.93, a reduction of about 14.2%[119]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[7]. - The total number of shares increased from 341,400,000 to 512,100,000, representing a 50% increase due to the capital reserve conversion[104]. - The largest shareholder, Xianju County State-owned Assets Investment Group Co., Ltd., held 21.55% of the shares, totaling 110,382,450 shares[107]. - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period[109]. Research and Development - Research and development investment increased by 45.31% to CNY 31,851,511.17, reflecting a focus on product innovation[33]. - The company has established long-term collaborations with several research institutions, including the Chinese Academy of Sciences and Zhejiang University, to enhance its R&D capabilities[42]. - The company received clinical trial approval for new drugs, including the active pharmaceutical ingredient and tablet form of a new drug[36]. Corporate Governance and Compliance - The company has maintained compliance with corporate governance standards as per relevant laws and regulations[73]. - There were no significant litigation or arbitration matters reported during the period[74]. - The financial report for the half-year period has not been audited[98]. Financial Instruments and Accounting Policies - The financial statements comply with the enterprise accounting standards, ensuring a true and complete reflection of the company's financial status[151]. - The company uses Renminbi as its functional currency for accounting purposes[153]. - The company recognizes revenue from the sale of goods when the following conditions are met: transfer of significant risks and rewards of ownership to the buyer, no retention of management rights associated with ownership, reliable measurement of revenue amount, likelihood of economic benefits inflow, and reliable measurement of related costs[200].